Dyskinesia market
February 3, 2012
A NEW report from GlobalData
has found that there is an unmet
need for the effective treatment of
dyskinesia despite the growing
numbers of Parkinson’s sufferers.
The global market for dyskinesia
therapeutics was valued at around
US$302.3m in 2011 and is expected
to reach US$480m by 2019,
however according to the report,
the dyskinesia therapeutics market
currently fails to cater to need due
to the absence of approved
products to treat the disorder.
“In order to reduce the risk of
tardive dyskinesia (TD), doctors are
attempting to shift the antipsychotics
prescription pattern from typical
antipsychotics, such as haloperidol,
to atypical antipsychotics, such as
olanzapine,” GlobalData said.
According to GlobalData’s
research, Xenazine (tetrabenazine),
a Huntington’s disease drug, is the
preferred off-treatment for TD,
despite it not being approved for
this use by the FDA or the EMA due
to “unfavourable side effects”.
“The dyskinesia therapeutics
developmental pipeline is weak,
with 13 molecules in various phases
of development,” GlobalData said,
adding that the late stage pipeline
has only one molecule, ADS-5102
from Adamas Pharmaceuticals,
currently in Phase II/III and estimated
to enter the market by 2016.
“However, this is a product
extension of amantadine and is not
expected to have a significant impact
on the market,” Global Data said.
The above article was sent to subscribers in Pharmacy Daily's issue from 03 Feb 12To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 03 Feb 12
